Israeli biomedical company Pluristem signed a cooperation agreement with the medical research centre of the University of Fukushima.
Under the agreement, the parties agreed on cooperation in the sphere of further development of Pluristem product PLX-R18 intended for the treatment of acute forms of radiation sickness and diseases caused by radiation treatment of oncological diseases.
The Israeli company will provide the product knowledge and technical support, and the medical centre will conduct research. In the first phase of the study will be carried out on animals. In case of success of the first phase, the University will take on the job of getting permission to test on humans.
University medical center Fukushima decision of the government of Japan was turned into a leading center for the study of diseases associated with radiation.
Recall that in 2011, earthquake and tsunami is out of order located in the Fukushima nuclear power plant, which led to a sharp increase in radioactivity in the region.